[{"orgOrder":0,"company":"Groupe Persavita","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase II","graph3":"Groupe Persavita","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Groupe Persavita \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Groupe Persavita \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Groupe Persavita

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : Persavita's experimental product is composed of three natural ingredients with known immune modulating properties. The company is gearing up to test this experimental product in Covid-19 patients through a phase 2 clinical study already authorized by Hea...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          November 20, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Pharmacology/Toxicology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank